Glowise editorial guide

Do GLP-1 Medicines Cause Cancer? What the Evidence Can Tell Us

Understand GLP-1 cancer research, the thyroid C-cell warning, MTC and MEN2 contraindications, and why study duration and cancer type matter.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 13, 20266 min read
Download the Glowise App

Share this guide

Xfin
An adult comparing a medicine guide with a research paper at a sunlit table, with a notebook open beside them

Human research has not established that GLP-1 medicines cause an overall increase in cancer. That does not establish zero risk for every cancer, medicine, or length of treatment. Some findings are reassuring; others remain uncertain. The thyroid warning on several widely used products is still part of their current U.S. prescribing information.

The apparent contradiction becomes clearer when you separate three questions: what happened in animals, what human studies have actually measured, and which warnings apply to your prescription. A finding about all cancers combined cannot, by itself, settle a question about one rare thyroid cancer.

Why the thyroid cancer warning exists

Semaglutide caused thyroid C-cell tumors in rodent studies. C-cells are a particular kind of thyroid cell; medullary thyroid carcinoma, or MTC, is the cancer named in the warning. The Wegovy label states that tumors occurred at clinically relevant exposures and that it is unknown whether Wegovy causes these tumors in humans.

That exposure detail matters. The animal finding cannot be dismissed as something seen only at doses far beyond human treatment. Equally, a tumor finding in rodents does not establish that a person taking the medicine will develop cancer. The label preserves an unresolved question about how those findings translate to people.

Tirzepatide, the dual GIP/GLP-1 medicine in Mounjaro and Zepbound, also has a thyroid C-cell tumor warning based on rat studies. Its human relevance remains unknown in the Mounjaro prescribing information. A broad claim that the warning has been disproved goes further than these labels do.

What human studies show—and how long they watched

Human studies answer different parts of the question. Randomized trials compare people assigned to treatment or a control. Observational studies examine care that happened outside a trial; they can include more people, but treatment choices and differences between groups complicate interpretation.

A randomized semaglutide trial offers useful reassurance

SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes. Over a mean follow-up of 39.8 months, malignant neoplasms—cancers—were reported in 4.8% of the semaglutide group and 4.7% of the placebo group, with no significant difference. These figures come from the original SELECT report.

This is meaningful evidence against a large overall cancer difference during that study. It is not a lifetime estimate, a cancer-prevention trial, or an answer for every GLP-1 product. The SELECT safety analysis also notes that people with malignant cancers within the previous five years were generally excluded, with specified exceptions. Someone receiving cancer treatment cannot assume that these results describe their situation.

A large thyroid study found no substantial increase, with limits

A 2024 Scandinavian cohort study compared people starting GLP-1 receptor agonists with people starting DPP-4 inhibitors, another diabetes-drug class. Thyroid cancer rates were 1.33 versus 1.46 cases per 10,000 person-years. A person-year represents one person's year of follow-up; these figures are not the percentage of users who will develop cancer.

The GLP-1 group's mean follow-up was 3.9 years. However, it was only 1.1 years for semaglutide users in that study. The estimate for MTC was imprecise because the cancer was rare. These results support reassurance within the observed period, while leaving uncertainty about MTC and much longer exposure to newer medicines.

The thyroid evidence is not uniformly negative

A 2025 analysis of 50 randomized trials found no statistically significant overall cancer difference, but did find a higher pooled occurrence of thyroid cancer. Its trials had a median duration of 65 weeks, and cancers were not prespecified outcomes. The authors identified limited event numbers and study duration as important constraints.

That signal deserves further investigation. It does not establish that GLP-1 medicines cause MTC, and it should not disappear from an explanation simply because another study was reassuring. The evidence supports a narrower answer than either “these drugs cause cancer” or “the cancer question is settled.”

Do GLP-1 medicines prevent cancer?

Some observational findings suggest lower rates of certain cancers, but the comparison group changes the answer. A 2024 U.S. medical-record study found lower rates of several obesity-associated cancers among adults with type 2 diabetes prescribed GLP-1 receptor agonists compared with insulin. Compared with metformin, it found no significant reduction for any of the cancers studied and found a higher kidney-cancer association.

These are associations, not proof that a medicine prevents or causes an individual cancer. People prescribed insulin, metformin, and GLP-1 medicines can differ in ways a record-based analysis cannot fully remove. Lower rates against one comparator do not make the drug a cancer-prevention treatment, and a higher rate against another does not alone prove a causal harm.

When a headline promises protection, ask: protection against which cancer, compared with which treatment, in which population, and over what period? Those details often explain why two headlines sound incompatible.

The MTC and MEN2 contraindications still apply

The current U.S. Ozempic prescribing information contraindicates use in people with a personal or family history of MTC, or in people with multiple endocrine neoplasia syndrome type 2, or MEN2. Wegovy, Mounjaro, and Zepbound have these cancer-related contraindications too. A contraindication means the product should not be used in that situation; reassuring population-level research does not override it.

The distinction is specific. A relative's history of “thyroid cancer” needs its exact diagnosis clarified, rather than being assumed to be MTC or assumed to be irrelevant. A different cancer history does not automatically equal this contraindication, but it still belongs in the prescriber's assessment. Bring the diagnosis or records when available. If you learn of a relevant personal or family MTC history, or MEN2, while taking one of these products, contact the prescriber promptly before another dose to address the contraindication.

These are examples from named products, not a substitute for checking the exact medicine and form you were prescribed. For the broader medical evaluation, see who qualifies for GLP-1 treatment.

Which symptoms or tests need attention?

The Zepbound label tells clinicians to counsel people about thyroid-tumor symptoms: a neck mass, difficulty swallowing, difficulty breathing, or persistent hoarseness. Tell your healthcare professional if these develop. A symptom warrants assessment; it does not identify a cancer or prove that medication caused it.

For routine screening, the Wegovy label says that checking calcitonin or using thyroid ultrasound routinely has uncertain value for early MTC detection. It also says that a thyroid nodule found on examination or imaging needs further evaluation. This separates blanket screening because of a prescription from investigating an actual finding. A test should answer a clinical question, rather than provide a certificate that future cancer risk is zero.

What to take into a prescribing conversation

Start with the exact product and the reason it is prescribed. Then ask about the cancer history or evidence that concerns you: “Does this diagnosis affect whether I can use this medicine?” or “How much follow-up does the study behind this headline actually have?” If you have a current or previous cancer diagnosis, include the treating team in that discussion.

You do not have to choose between ignoring a warning and assuming it predicts your future. The useful decision combines the medicine's expected benefit for your condition, its current contraindications, your history, and the limits of available follow-up. Cancer evidence can inform that decision without promising certainty it has not earned.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.